COMMUNIQUÉS West-GlobeNewswire

Predictive Technology Group Announces Opening of New Laboratory Facilities
11/09/2018
SALT LAKE CITY, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC/PINK: PRED), a life-sciences technology company, announces its subsidiary Predictive Biotech has completed phase one of its new [...]
Exagen, Maker of AVISE Testing, Announces First Blood Test for Anti-CarP, a Breakthrough Bio-marker for Rheumatoid Arthritis
11/09/2018
Novel Test Now Available to Aid in Detection and Management of Widespread Debilitating Condition San Diego, CA and Albuquerque, NM, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Exagen Diagnostics, the leader in specialty [...]
Radius Health to Present at the Morgan Stanley 16th Annual Global Health Care Conference
11/09/2018
WALTHAM, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that Jesper Høiland, President and CEO, and Pepe Carmona, Chief Financial Officer of the Company, will present a [...]
CalibreScientific Acquires PhytoTechnology Laboratories, a Leading Provider of Plant Molecular Biology and Plant Tissue Culture Research Products
11/09/2018
LOS ANGELES, Sept. 11, 2018 (GLOBE NEWSWIRE) -- CalibreScientific is pleased to announce that it has completed the acquisition of PhytoTechnology Laboratories, LLC (“PhytoTech Labs“ or the “Company”), a provider of [...]
Q-Centrix Launches Innovative Data Management Initiative Focused on Enabling Hospitals to Keep up with Modern Quality Reporting Demands
11/09/2018
The effort combines data automation technologies, human-centered design, and behavioral economics factors to drive more efficient and cost-effective processes to advance hospitals’ healthcare quality reporting [...]
Marrone Bio Innovations Appoints Jenna Combs as Sales Manager of Northern California Territory
11/09/2018
DAVIS, Calif., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental [...]
Precision Therapeutics Appoints Dr. Amelia Warner to Scientific Advisory Board
11/09/2018
MINNEAPOLIS, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery [...]
CellAegis Announces Completion of Patient Enrollment in First North American Study for Innovative Heart Attack Therapy Using autoRIC®
11/09/2018
TORONTO, Sept. 11, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for [...]
Advanced Proteome Therapeutics Provides Overview of Current Activities and Strategic Objectives
11/09/2018
VANCOUVER, British Columbia, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) , is pleased to provide an overview of current projects prior to [...]
Viveve Submits Investigational Device Exemption to FDA to Conduct LIBERATE-U.S. Trial for Improvement of Stress Urinary Incontinence
11/09/2018
ENGLEWOOD, Colo., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced submission of an Investigational Device [...]
Vectura Group plc: Interim Results
11/09/2018
This contains inside information Vectura Group plc Vectura regaining momentum with continued inhaled revenue and adjusted EBITDA growth Chippenham, UK - 11 September 2018 : Vectura Group plc (LSE: VEC) ("Vectura" or " [...]
ORYZON receives approval to start ALICE: a Phase IIa clinical trial in AML with Iadademstat (ORY-1001)
11/09/2018
The study will be done in elderly Acute Myeloid Leukemia (AML) patients not eligible for intensive chemotherapy It is the first Phase II study of Iadademstat (ORY-1001) in combination therapy MADRID, Spain and CAMBRIDGE [...]
Tetra Bio-Pharma Accelerates its European Drug Registration Activities
11/09/2018
PPP001 and PPP005 Eligible for Marketing Approval ORLEANS, Ontario, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc . (" Tetra " or the " Corporation ") (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in [...]
Atara Biotherapeutics Appoints Cancer Research and Clinical Development Veteran, Roy Baynes, to its Board of Directors
11/09/2018
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]
BioSig Technologies Issues Shareholder Letter
11/09/2018
Highlights include FDA 510(k) clearance and Nasdaq uplisting Santa Monica, CA, Sept. 11, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB:BSGM, OTCQB:BSGMD) a medical device company developing a proprietary [...]
Professor Cosman Redefines Robotic Surgery in Australia
11/09/2018
BRIGHTON, Mich., Sept. 11, 2018 (GLOBE NEWSWIRE) -- FlexDex Inc. is pleased to announce the first surgical procedure performed utilizing the FlexDex ® Needle Driver took place on July 31, 2018 in Australia. Prof. Peter [...]
Invuity Announces Definitive Agreement to Be Acquired by Stryker Corporation for $7.40 Per Share in Cash
11/09/2018
SAN FRANCISCO, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ: IVTY), a leading medical technology company focused on advanced surgical devices to enable better visualization, today announced it has entered [...]
KemPharm Announces Positive Topline Results from Oral Human Abuse Potential Trial of KP415 Prodrug
11/09/2018
Highlights of KP415.A01 Oral HAP Trial Results: Mean Drug Liking (E max ) of KP415 Prodrug (serdexmethylphenidate) at both 120 mg and 240 mg doses were statistically significantly lower than Focalin ® XR at 80 mg Mean [...]
IMV Inc. Announces Phase 2 Basket Trial in Collaboration with Merck to Evaluate DPX-Survivac in Combination with KEYTRUDA® Across Five Solid Tumor Indications
11/09/2018
Clinical Expansion Marks Third Phase 2 Clinical Trial Combining IMV’s Lead Immunotherapy Candidate with Merck’s Marketed Checkpoint Inhibitor HALIFAX, Nova Scotia, Sept. 11, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: [...]

Pages